INSIGHTS, FACTS & FIGURES
Centre for Reproductive Medicine Brussels 2020 annual report
2020 at a glance 04 Preface 06 About the Centre for Reproductive Medicine 08
CRG Staff 10 In-vitro maturation 14 The COVID pandemic 20 Quality assurance & patient satisfaction 24
TABLE OF CONTENT
Scientific research & training 26 Reproductive Skills Centre Brussels 36 CRG in the press 38
Page 4 - Annual report CRG
2020
at a glance
13,915* patient consultations
3,472
*58% tele-consultations
patient counseling sessions
1,082
1,841
surgical
intra-uterine inseminations
interventions
16,898
ultrasounds
36,847
blood samples
3,586
egg collections
5,367 embryo transfers
465
Preimplantation Genetic Testings
3,485 frozen embryo transfers 1,883 fresh embryo transfers
85
oncofertility interventions
Annual report CRG - Page 5
BELRAP overview* * Belgian Register for Assisted Procreation - 2018 data on 34 Belgian IVF centres (incl. 18 B-centres)
29% of all IVF treatments in Belgium are performed at CRG 40.5% chance of a live born child for fresh embryo transfer in reference group (vs. rest of Belgian centres: 28.2%)
32% chance that an embryo will implant and give rise to a live birth if under 36 years (all ranks)
(vs. rest of Belgian centres: 23%)
CRG
performs:
86% of all IVM cycles 71% of all ICSI cycles with surgically retrieved sperm 64% of all oocyte donations 39% of all oocyte banking cycles
Research 122 peer-reviewed papers or abstracts 2,270 peer-reviewed publications and
abstracts from 1983 until 2020
30+ ongoing research projects
CRG staff
200+
employees, including:
25+
fertility doctors
Page 6 - Annual report CRG
Dear colleague, Dear reader, Dear employee, As for many, 2020 was an annus horribilis for the Centre for Reproductive Medicine (CRG). Belgium, and in particular the Brussels region, was confronted with two COVID-19 waves and the COVID-19 crisis turned out to be an unprecedented stress test for the entire healthcare sector. In our country, during the first wave, from March to May, the government requested that all nonCOVID-19 related care be stopped. During the second wave starting in October, Brussels hospitals, including ours, were flooded with COVID-19 patients, triggering a proactive step-by-step plan to deal with this new tsunami. Just like in the first wave, a large part of our CRG staff was reallocated to other services, which forced us to halt to our activities for a second time. We closed this year with about 3600 IVF cycles, which is 35% less than in 2019 and roughly the same number as in 2007. Our surgical activities suffered to the same extent from the COVID troubles.
The overall impact on the CRG is heavy, but this is of course relative when we look at the human impact: many of us lost loved ones, many of us went through a psychological rollercoaster, many of us sometimes wondered what we were doing. Our patients sometimes felt abandoned and often made their voices heard through the press and social media. Many thanks and respect go to the CRG staff who stepped far outside their comfort zone and gave their best to ride the waves, always trying to help our patients wherever and whenever possible. Thankfully, towards the end of the year, the situation in Brussels cleared up somewhat, allowing us to restart our IVF programme in full as from January of this year. Now, in the middle of a third wave, our IVF activities continue unabated, but once again we are forced to reduce our surgical activities. Every crisis calls for flexibility and progressive insights. New trends emerge, old habits disappear. Some things gain momentum, others die a quiet death. COVID-19 did prompt us to adapt our five-year strategic plan that we launched in 2020 and made it COVID-proof. For example, there was an accelerated implementation of digitalisation for staff working from home, patient contacts, meetings and educational activities. We introduced a hybrid meeting model with a limited number of people physically present linked to a parallel digital meeting. This quickly became the standard and will probably remain so. This year, our CRG app will be rolled out, which will facilitate communication with our patients, and our CRG website and
Annual report CRG - Page 7
CRG look-and-feel will be rebranded. Our training activities will be supported through digital modules where possible. In the meantime, we have all been vaccinated and look forward to life as before. Hopefully we will soon be able to welcome back our international patients and peers. 2020 was an eventful year, the COVID-19 crisis created a lot of uncertainty. The inventiveness and flexibility that our employees showed and continue to show in dealing with this crisis asks for respect and admiration.
Preface Prof. dr. Herman Tournaye Medical and Scientific Director Centre for Reproductive Medicine
We hope to be able to grow again from this year onwards and to continue our activities unabated. For the CRG, 2018 was a grand-cru year, 2019 a millésime, and 2020 was the year of… decontamination alcohol. But hopefully, 2021 will be another banner year!
Page 8 - Annual report CRG
About the Centre for Reproductive Medicine Since 1983, the Centre for Reproductive Medicine has been active within UZ Brussel, the university hospital of the Free University of Brussels (VUB). As a centre specializing in reproductive medicine, the CRG has performed groundbreaking work developing and improving reproductive techniques and their application. A worldwide breakthrough was realized in 1991 with the introduction of the ICSI technique. The CRG’s success is also based on continuous scientific research. For decades, our centre has been at the forefront of its expertise, both nationally and internationally. In 2020, over 50,000 children are born as a result of their parents’ treatment at the CRG. In normal times, about 20% of patients attending the CRG come from abroad. The centre now accounts for almost 30% of in-vitro fertilization treatments carried out in Belgium (based on the latest Belrap data). For years, it has achieved markedly higher pregnancy and live birth rates than the national average. The CRG is compliant with the highest international quality standards (ISO 15224:2017 and ISO 15189:2012). The Reproductive Skills Centre Brussels is the CRG’s in-house training centre. Moreover, the CRG provides accredited
trainings for the European Board and College for OBGYN (EBCOG), the European Society of Human Reproduction and Embryology (ESHRE) and the European Academy for Andrology (EAA). The CRG is a certified ESHRE centre for good clinical practice. The collaboration with the medical genetics centre of UZ Brussel (CMG) also results in a top position in Europe for embryo testing. Scientific research lies at the heart of the CRG activities. Our researchers are also members of the Reproduction and Genetics research groups at VUB. From its inception, the centre has played a pioneering role in the development and study of reproductive techniques, partly thanks to its drive for scientific excellence. Pioneering techniques include genetic analysis of embryos before transferring them back to the uterus freezing of oocytes, in-vitro maturation of oocytes (IVM) followed by fertilisation. Our researchers are also working on methods to safeguard the fertility of patients who must undergo chemo- or radiotherapy, i.e. treatments that negatively affect fertility; stem-cell therapies and the development of stem-cell lines.
Annual report CRG - Page 9
A fertility clinic with a broad range of care The CRG offers its patients a broad care programme, ranging from assisted reproduction to the treatment of related reproductive problems: • • • • • • • • • • • • •
Ovulation induction and timed intercourse Artificial insemination IVF and ICSI Surgery for sperm extraction, including micro TESE Microsurgical vasectomy reversal IVM (in-vitro maturation) IVF/ICSI programme for prospective parents with a viral infection (HIV, hepatitis) PGT programme for couples with a hereditary condition or for embryo selection Recurrent miscarriage clinic Treatments with third-party gametes (donor sperm, donor eggs) Fertility preservation for patients with a cancer diagnosis (both male and female, including prepubertal patients) AGE banking (social freezing) Gestational surrogacy
About UZ Brussel & VUB Universitair Ziekenhuis Brussel (University Hospital Brussels) stands for quality medical care. It offers both basic care and innovative, hightech healthcare solutions at regional, national and international level at an affordable cost. The hospital’s clinical excellence, scientific commitment and human-oriented tuition ensure the highest degree of competence in many fields. The more than 3,800 multilingual employees are driven by the patients’ quality of life. Care is provided in a respectful way, regardless of origin, language or religion. Vrije Universiteit Brussel (VUB, the Free University of Brussels) is a dynamic and modern university with two parkland campuses in the Brussels Capital Region. The main campus in Etterbeek is home to seven faculties. The medical campus and UZ Brussel, the university hospital, which incorporates the Centre for Reproductive Medicine, are located in Jette at the Brussels Health Campus.
Our fertility experts
Prof. dr. Herman Tournaye - Head of Department Expertise: Andrology & Oncofertility
Prof. dr. Michel De Vos - Senior Medical Director Expertise: Reproductive endocrinology - oncofertility
Prof. dr. Willem Verpoest - Senior Medical Director Expertise: Reproductive genetics & Immunology
Prof. dr. Christophe Blockeel - Senior Medical Director Expertise: Reproductive endocrinology
Annual report CRG - Page 11
Dr. Veerle Vloeberghs - Medical Director Expertise: Andrology & Oncofertility
Dr. Liese Boudry - Junior Medical Director Expertise: Reproductive infectiology
Dr. Valerie Schutyser - Medical Director Expertise: Reproductive surgery
Prof. dr. Shari Mackens - Junior Medical Director Expertise: Recurrent miscarriage and implantation failure
Page 12 - Annual report CRG
Our fertility experts: consultants and clinical fellows
Prof. dr. Michel Camus - Senior Consultant
Prof. dr. Michael De Brucker - Consultant
Dr. Guy Verhulst - Consultant
Dr. Sylvie De Rijdt - Consultant
Dr. Laurence Strypstein - Senior Clinical Fellow
Dr. Sien Delattre - Senior Clinical Fellow
Annual report CRG - Page 13
Dr. Caroline Roelens - Senior Clinical Fellow
Dr. Jana Claeys - Junior Clinical Fellow
Dr. Michelle Soares - Junior Clinical Fellow
Dr. Sophie Hendrickx - Junior Clinical Fellow
Dr. Lynn Opdecam - Junior Clinical Fellow
Dr. Sophie Pommé - Clinical Fellow-in-training
Research Fellows: • • • • •
Dr. Maxime Vromman - Clinical Fellow-in-training
Dr. Panagiotis Drakopoulos Dr. Biljana Popovic Dr. Annalisa Racca Dr. Erlisa Bardhi Dr. Francisca Pais
Our fertility experts: clinical fellows & research fellows
FOCUS ON
In-vitro maturation
INTERVIEW Prof. dr. Michel De Vos Michel De Vos, MD, PhD, is a gynaecologist and an associate professor in reproductive medicine and senior medical director at the Centre for Reproductive Medicine (CRG) at UZ Brussel - Vrije Universiteit Brussel (VUB). He studied medicine in Ghent and holds a PhD in medicine from the University of Leeds, UK. He joined the CRG team in 2006 after an OBGYN training at VUB. In 2011, he was recognised as a subspecialist in reproductive medicine and surgery by the European Society of Human Reproduction and Embryology (ESHRE) and the European Board and College of Obstetrics and Gynaecology (EBCOG). His current research activities are focused on reproductive endocrinology, polycystic ovary syndrome, in-vitro maturation of oocytes and fertility preservation.
Can you tell us about in-vitro maturation treatment and its history? In-vitro maturation (IVM) of oocytes (eggs) is a laboratory technique that makes it possible to obtain mature oocytes for in-vitro fertilisation after harvesting unripe oocytes from the ovaries and culturing these oocytes in the lab.1 In-vitro maturation means ‘ripening’ of oocytes in a test tube in a specific culture environment in the laboratory.
“A technique discovered almost 100 years ago allows oocytes to mature in the laboratory” IVM can be used as an artificial reproduction technique for selected patients: we perform an oocyte pick-up under ultrasound control and retrieve immature oocytes from small antral follicles. The immature oocytes are subsequently matured in the laboratory in a specific culture environment for approximately 30 hours. After maturation
of the oocytes, approximately 50% will have matured. Those oocytes that have become fully mature can be fertilised with sperm from the partner or donor, or cryopreserved for future use. The IVM technique was discovered almost 100 years ago. The first experiments describing that oocytes could mature in vitro date back to 1935 in the rabbit. The IVM technique in humans was first described by Menkin and Rock in 1944.2 Bob Edwards, IVF pioneer, also focused on in-vitro maturation in the 1960s, in the early years of his career. The first clinical application dates back to the early 1990s. The first IVM baby was born in 1992 in Australia. Subsequently, IVM activity had its ups and downs, and it was only in the late 1990s that interest in this technique returned, mainly in Canada. After the turn of the century, we picked it up at our CRG. In 2008, I travelled to Canada in order to learn how to perform an oocyte retrieval for IVM. We started laboratory research in our centre in 2008, in collaboration with the Follicle Biology research group at VUB. From the beginning of 2010 onwards, IVM was also applied in the CRG clinic, after which the first IVM baby was born on 1 November 2010, named Juliette. She was the first IVM baby in Belgium.
What is the role of IVM in oncofertility and PCOS patients?
“The possibility to harvest oocytes sooner can provide a safer option for cancer patients.” The IVM technique has mainly been applied in oncofertility cases and as fertility treatment for selected patients with polycystic ovary syndrome (PCOS). It has long been possible for young women with a diagnosis of cancer to have mature oocytes banked after a course of hormonal stimulation followed by an oocyte retrieval. The problem is that hormonal stimulation usually takes two to three weeks. For some cancers, it is unsafe to delay the start of oncological treatment by two to three weeks. Harvesting immature oocytes offers a valid alternative. An ovarian pick-up to harvest immature oocytes can be planned urgently, without prior stimulation treatment. The collected immature oocytes can mature in the laboratory and then be cryopreserved. For oncological patients with hormone-sensitive tumours in patients who prefer not to have hormonal injections for ovarian stimulation, IVM is also a safe alternative for oocyte banking.
Page 16 - Annual report CRG
“Experimental research achieved success by freezing the ovarian cortex and transplanting the tissue later.” A recent, but experimental application of IVM focuses on cancer patients who have ovarian tissue surgically removed for cryopreservation. By freezing the ovarian cortex, we preserve the primordial follicles that are stored there. The tissue can be transplanted later, after being cured from cancer, should the patient be confornted with ovarian insufficiency due to the cancer treatment. By transplanting thawed ovarian tissue, we try to restore ovarian function. This is mainly done in the context of urgent cancer treatment or in prepubertal girls with cancer. After all, no hormonal stimulation can be applied before puberty. Interestingly, we have shown that it is feasible to identify immature oocytes during ovarian tissue processing in the context of ovarian tissue freezing. These immature oocytes are recovered from the ovary ex vivo and can mature in-vitro. In recent years we have seen a number of patients, so called cancer survivors, coming back to use their cryopreserved eggs that has been derived from ex vivo immature oocytes. In an importantly subset of these patients, a pregnancy was achieved using these ex-vivo oocytes, which has been considered an important milestone in the field of oncofertility. 3,4
Women with polycystic ovarian syndrome (PCOS) are another important group of patients eligible for IVM treatment. Up to 10% of all young women suffer from PCOS. More than one third of them consult a fertility specialist for their unfulfilled desire to have children, mostly due to ovulation disorders.
“Harvesting oocytes without hormone treatment can reduce risk for women suffering from PCOS.” With standard IVF treatment, women with PCOS have an increased risk of ovarian hyperstimulation syndrome (OHSS) and other side effects of the hormone treatment. Because there is little therapeutic margin to adjust the ovarian response to the gonadotrophins, the outcome of standard treatment is sometimes disappointing. At the same time, women with PCOS have a large supply of antral follicles. The development of these follicles is hindered by a high concentration of antimullerian hormone (AMH), as high AMH levels inhibit proper ovulatory function. For IVM, however, high AMH values are a blessing: the success rate of the treatment depends largely on the available supply of antral follicles. The higher the AMH, the more oocytes we can collect and mature and the greater the chance that several embryos will develop after fertilisation and that a live birth can be achieved.
Annual report CRG - Page 17
“Depending on specific individual circumstances IVM should not be addressed as a last resort but should be a timely considered treatment plan to best serve the patient.” However, we have seen that the switch to IVM is often made only after several attempts with classic IVF in other centres. We would like to emphasise that selected patients in whom standard ovarian stimulation for IVF leads to suboptimal outcomes may be referred to us sooner for IVM treatment. At the PCOS clinic, in addition to IVM treatment, it is important that the patient is in an optimal state of health before starting an IVM treatment. Attention is paid to the total package; all aspects of this condition are addressed by combining expertise in different fields (dermatology, diabetology, etc.). We have recently established a multidisciplinary clinic at UZ Brussel to provide care for women with PCOS at multiple levels beyond the reproductive care. Furthermore, patients with ovaries that are resistant to ovarian stimulation (women with FSH resistance due to a mutation in the FSH receptor) also qualify for IVM treatment.5 Can you inform us about the success rates? The type of patient is important for the success rate of IVM, more specifically PCOS patients with high AMH concentration at the most severe end of the PCOS spectrum have the highest chances of a live birth with IVM. The higher the AMH concentration, the more antral follicles are present and the more oocytes can be obtained.
“On average the success rate of IVM is not as high as with conventional IVF, but there are fewer side effects and fewer hormonal injections are administered” There is a 40% chance of having a child per IVM cycle, per oocyte retrieval.6 On average, this is not as high as with conventional IVF, but the technique is more patient-friendly. There are fewer side effects and fewer hormonal injections are administered. In a social context, this type of treatment is also less burdensome for the active woman. At the first consultation, the day
of ovarian pick-up can already be determined. There is no other fertility treatment that allows patients and care providers to precisely schedule the day of oocyte retrieval. Indeed, the ovarian pick-up with IVM is not based on ovarian response, which makes it easier to schedule. Stimulation is administered for a maximum of only 3 days, which is a very important advantage. Everything is reduced to a strict minimum: far fewer blood tests, ultrasound checks, monitoring. The workload for the patient is minimal.
“Studies show the lower impact of the treatment can increase the mental health of patients involved.” This low impact on the woman’s busy life translates furthermore into better quality of life. This ‘quality of life’ and the mental health of the patient during IVM treatment is examined on the basis of completed questionnaires before, during and after IVM treatment. We are currently conducting a questionnaire-based study to assess whether the mental impact of IVM is less than that of standard ovarian stimulation and IVF. We hope to find scientific evidence that the advantages for the mental well-being of the patient compensate for the slightly lower success rate per treatment.
“An average of 150 IVM cycles are performed each year. This is 3% of the total ovarian pick-ups in our centre” An average of 150 IVM cycles are performed each year, which is about 3% of the total ovarian pick-ups performed in our centre. This is only a small proportion, but it is important to report that only a limited number of PCOS patients are eligible for IVM treatment. The majority of PCOS patients will become pregnant after ovulation induction and will not need IVM or IVF. Only when no pregnancy occurs after several attempts of ovulation induction, or when sperm quality is poor, IVF or IVM is considered, and only the extreme cases are eligible for IVM eventually. Sometimes ‘rescue IVM’ is also applied when immature oocytes are obtained after ovarian stimulation. This is not the real IVM that we apply today. With this technique, an attempt is made to allow the immature oocytes, which are obtained after ovarian pick-up with classic stimulation, to still mature. However, experience
Page 18 - Annual report CRG
has shown that this ‘rescue IVM’ does not work as hoped; the chance of success is limited since the layer of cumulus cells around the oocytes are removed after ovarian pick-up following a classical stimulation. The cumulus cells, however, support the oocytes and thus allow them to mature (by exchanging nutrients and signals). The IVM application to ‘naked oocytes’ (oocytes without the cumulus cells) does therefore not have the desired effect as with the standard IVM, as the support of the cumulus cells in the maturation process is omitted here. We are one of the few centres in Europe that apply IVM. What makes us unique? Together with some colleagues from Asia, Australia, the US and Europe I have created a ‘IVM special interest group’. This interest group is in the process of applying to become recognised by ASRM (American Society for Reproductive Medicine). The main purpose of this global special interest group is to give and ask attention for the advantages of IVM worldwide. The aim is to create a network of IVM expert centres in order to train other centres in IVM. At the CRG of UZ Brussel, the Reproductive Skills Centre Brussels is an important training centre for this IVM technique. Nevertheless, with the growing group of cancer patients - and the fact that fertility preservation is reimbursed in Belgium since 2017 - there is a great chance that other centres may be interested in applying IVM to cancer patients.
“Recreating optimal conditions for maturation in the laboratory needs the right expertise to allow this technique to be the most appropriate treatment.” On the other hand, for PCOS patients, we are a centre that can offer the most appropriate treatment, within Belgium and Europe. As it is not easy to recreate the optimal conditions for maturation in the laboratory as it is in the female body, this might be one of the most important reasons why not all centres have ventured into this technique. We ourselves had to refine the technique during the first years. In the beginning, many of our employees volunteered to undergo an oocyte retrieval for our scientific research in IVM. There are still many volunteers who help us in our research, supported by a number of funding bodies (currently FWO). Funding is still an important link in the continuation of our research into ever better and more refined techniques.
What is the future of IVM in fertility medicine? Without wishing to claim that classical IVF as a fertility technique has passed its peak, we are seeing an increasing demand from patients for a shorter, less hormonal aggravating and safer treatment. A treatment that has less impact on mental well-being. IVM treatment cannot compete with the standard IVF procedure in terms of efficiency, but it may offer a better balance between success rate and burden for the patient. The number of followup visits is lower, fewer injections are needed for ovarian stimulation and the cost of medication is significantly lower than for conventional IVF treatment. However, with all the assets this treatment offers, it will probably remain an interesting treatment for a subset of patients, specifically those with PCOS, FSH resistance and urgent fertility preservation.
References 1. De Vos, M., Smitz, J., Thompson, J. G., & Gilchrist, R. B. (2016). The definition of IVM is clear-variations need defining. Human Reproduction, 31(11), 2411–2415. http://doi.org/10.1093/humrep/ dew208 2. Rock, J., & Menkin, M. F. (1944). In vitro fertilisation and cleavage of human ovarian eggs. Science (New York, NY), 100(2588), 105. 3. Segers, I., Bardhi, E., Mateizel, I., Van Moer, E., Schots, R., Verheyen, G., et al. (2020). Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes. Human Reproduction (Oxford, England), 31(32-37), 750–11. http://doi.org/10.1093/humrep/deaa175 4. Segers, I., Mateizel, I., Van Moer, E., Smitz, J., Tournaye, H., Verheyen, G., & De Vos, M. (2015). In vitro maturation (IVM) of oocytes recovered from ovariectomy specimens in the laboratory: a promising “ex vivo” method of oocyte cryopreservation resulting in the first report of an ongoing pregnancy in Europe. Journal of Assisted Reproduction and Genetics, 32(8), 1221–1231. http://doi.org/10.1007/s10815-015-0528-9 5. Galvão, A., Segers, I., Smitz, J., Tournaye, H., & De Vos, M. (2018). In vitro maturation (IVM) of oocytes in patients with resistant ovary syndrome and in patients with repeated deficient oocyte maturation. Journal of Assisted Reproduction and Genetics, 208(2), 349–11. http://doi.org/10.1007/s10815-018-1317-z 6. Mackens, S., Pareyn, S., Drakopoulos, P., Deckers, T., Mostinckx, L., Blockeel, C., et al. (2020). Outcome of in-vitro oocyte maturation in patients with PCOS: does phenotype have an impact? Human Reproduction (Oxford, England), 96, 860–8. http://doi.org/10.1093/humrep/deaa190
CONTACT US FOR MORE INFORMATION ON IN-VITRO MATURATION The responsible physician at the CRG is Prof. dr. Michel De Vos. Oncofertility Coordinator Ellen Van Moer +32 2 477 40 44 info@brusselsoncofertility.be www.brusselsoncofertility.be
PCOS Clinic Coordinator Linde Mostinckx +32 2 476 37 54 PCOSclinic@uzbrussel.be www.uzbrussel.be/web/pcos-kliniek
IVM training at Reproductive Skills Centre Brussels Management assistant Lien Wets +32 2 477 66 62 lien.wets@uzbrussel.be https://reproductiveskillscentre.com
For the scientific programme, there is a cooperation with research group FOBI (Follicle Biology) at the Vrije Universiteit Brussel to further develop the IVM technique.
FOCUS ON
The COVID-19 pandemic
and its impact on our activities As in all other sectors worldwide, the COVID-19 pandemic has had a huge impact on the CRG’s core business. This in terms of volume of activity, daily management of the department and deployment of our resources. COVID-19, and the extensive measures taken by our government and hospital to contain the virus, had an immediate and significant impact on our patients, our staff, our daily activities and, of course, our results for 2020.
The CRG’s ART activities were twice reduced and interrupted in a controlled manner to a complete standstill. This happened a first time in late March 2020 by order of the federal government as part of the national lockdown whereby all non-essential care was put on hold in the area of public health. A second interruption of our activity followed in early November 2020, when the second wave hit, at the request of the hospital management in order to be able to provide sufficient resources and care from our service to the departments facing an increasing number of COVID-19 infections. During these two COVID-19 waves, the CRG staff was massively deployed in the departments where they could support the continuity of both COVID and non-COVID care both in the immediate patient care and through logistical support. CRG midwives and lab assistants were deployed in COVID nursing wards, the emergency department and maternity wards, where they also took on night shifts. Through intensive crash courses, midwives and nurses were prepared to work on the medium intensive care units. Paramedics as well as administrative personnel started working as ‘buddies’ in day and night shifts, providing, among other things, non-medical and logistical support to health care workers in the COVID units.
UZ Brussel COVID-19 daily evolution: 31/12 - 7h
Others, such as staff members went on to provide organizational and management support to the central OR and Intensive Care Unit.
CRG managers and supervisors, meanwhile, remained on-site to monitor, manage and support the reallocated staff from close by.
Others still, went to help out in the ‘sewing workshop’ at the VUB university campus. Here, staff offered their know-how, sewing skills and sewing machines and produced hundreds of mouth masks and aprons from sterile sheets when supplies were short.
Some of the staff continued to work in CRG’s own services to ensure permanence, urgency and continuity in non-direct patient care and laboratories.
Our fertility doctors and midwives created and staffed the Intensive Care COVID Call Centre, contacting family members of hospitalized patients 7/7 with news of their loved ones. During these intensive and exhausting weeks and months, our CRG psychologists provided mental support and relief in meetings and debriefing moments with the key phrase being “social distancing but emotional closeness”.
Our own CRG infrastructure and medical and technical equipment was also voluntarily offered to other hospital departments that needed it more at the time. For example, during both waves, the Intensive Care Unit for children was housed at the level of the CRG operating theatre. From December 2020 onwards, a number of activities were resumed in phases, resulting in all care being reorganized and offered to our patients at 100% capacity from January 2021 onwards.
Page 22 - Annual report CRG Both the reduction and restart of activities, as well as the deployment and management during both waves, were centrally managed by a designated internal multidisciplinary working group. Digital, internal and external communication, as well as website and media were frequently used to communicate rapidly changing situations and data optimally. Operating plans were drawn up on the basis of procedures and quality standards. Conversely, procedures were also tested, validated and implemented through the quality system. Correct, prompt and empathetic communication to our patients was of primary importance. The CRG website and information screens were, at te height of the pandemic, updated almost daily. Patients whose treatment was to cease were called one by one, and were recontacted when activities resumed in January 2021. A number of procedures and operational scenarios that were introduced or modified (at an accelerated pace) as a result of the pandemic have proven to be useful even after the two COVID waves and the restart of activities. For example, teleconsultations, optimal management of waiting and work areas, working from home by employees, virtual meetings and the advance registration of all ambulatory (blood) tests will continue on, even after the pandemic.
As a result of these measures, the overall activity for 2020 was reduced to approximately two thirds of the normal volume.
The medical care and services provided by ART remain the first and most important pillar, but during this pandemic the presence of quality standards, procedures, good communication, operational management and control have also proven their worth in providing the best qualitative medical care within ART.
Annual report CRG - Page 23
CRG staff in the COVID-19 front line
Page 24 - Annual report CRG
FOCUS ON
Quality assurance & patient satisfaction Quality is serious business at CRG. We have always set high standards in terms of the quality of our actions and products. The CRG applies a different ISO standard in its laboratories than in its clinical operation, but both are integrated in one digital quality management system. CRG Laboratory – ISO-15189:2012 In 2005 the Assisted Reproductive Treatment laboratory of the CRG was awarded ISO accreditation, making it a pioneer in Belgium and in Europe. This is the strictest certificate for medical laboratories and for many years now it has been the standard at the CRG laboratories. CRG Clinic – ISO EN-15224:2017 For the clinical part, the CRG opted for the ISO EN15224:2017 certificate for healthcare, a specific version of the widely known ISO-9001 standard for the healthcare sector. This standard highlights the quality of the care process and patient-centred care. Quality as an ongoing process The quality story does not end at the implementation and proper application of all agreements and procedures. Because a quality system obviously needs ongoing maintenance and stimulation. That is why we carry out risk analysis and management. The risks need to be mapped and analysed for every process. We encourage staff to register ideas, complaints and anomalies. We study these and implement solutions. This usually results in improvement measures which, in turn, are evaluated at a later date. In this way we achieve a continuous improvement process. To measure is to know To measure the performance of the actions and treatments, we use performance indicators, both for clinical and
laboratory actions and treatments. The systematic followup of important parameters which determine the success of the treatment both individually and globally, yields important information which may result in a fine-tuning of the process or extra training. Solid identification system Quite unique is the IVF Witness identification system that the CRG has been using since 2010. This system is based on RFID technology. For each patient an IVF-identity card is created, RFID-identification labels are put on all receptacles with patient material and the identity of the RFID-sticker is automatically read at every workstation. Any wrong combination automatically results in an alarm signal, making mistakes and mixing up gametes and embryos virtually impossible. Internal and external evaluation And finally, each element of the quality system is regularly subject to critical evaluation: based on internal audits, conducted by staff members of the department. And as a result of this, if necessary, the procedure is adjusted; through regular external audits the supervisory body assesses whether the laboratories and CRG clinic still meet the awarded ISO-standard or certification requirements. Patient feedback and patient satisfaction Patients are at the centre of the CRG. We have a long history of conducting patient satisfaction surveys and involve patients in our operation and strategy. We take patient feedback and complaints very seriously. A dedicated quality manager follows up on these complaints and tries to find a solution together with the patient. Feedback & complaints Mrs. Dina Brackman Quality manager CRG Clinic Email: CRGpatientfeedback@uzbrussel.be
ISO 15189:2012
Some quotes from the patient satisfaction survey “The mixture between scientific, efficient, friendly and relaxed, I feel that this is unique to the CRG. I was in very, very good hands!” “Our journey has been a roller coaster, as expected, and as it is for the majority of women who visit and receive treatment at CRG. The clinic is doing great job and it is a magnificent privilege that individuals have this possibility to have babies. On top of that we came across with some exceptional personnel.” “During the embryo transfer the doctor was very considerate toward us, she explained the whole process and she was telling each step she was doing. I was treated as a human being. Totally different from my first experience, which felt too hasty.”
Patient complaints 0.14% of all provided services 2.30% of all interventions
Patient satisfaction 90% of patients would recommend the CRG to others
Internal reporting Ideas, complaints, deviations were reported in 0.20% of all clinical acts in 3.20% of all technical clinical acts in 1.14% of all laboratory services
“I would like more attention for the woman (holistic) and not only the process of creating an embryo/ pregnancy. More contact with the doctors, the patient monitoring is good for communicating (practical) information but it is not the same as a medical consultation.” “After 3 failed attempts outside Belgium and with not extremely positive overall experience, we came to CRG where we were listened to. No one ever gave us impression that we are asking too many questions and they are not at the right medical level. At our first consultation, I could not believe that there was no time pressure and whatever we asked it was explained to us.“ “For the first time in 1.5 years I felt that I was actually at being heard and got support instead of getting out stressed that I took up time to ask ‘unnecessary’ questions! We believe that if you give this level of comfort to the patient at the initial consultation and through out the treatment, things can go only better.” “A huge thank you to all your wonderful staff every single person I’ve interacted with over 3 years coming to your centre has been kind, professional, encouraging, warm and highly competent. I’ve had 3 fresh ICSI cycles and 3 frozen embryo cycles with you. This has resulted in my wonderful 20 month old son, and currently my 9 week pregnancy. I’ve also had 3 failed cycles and one early miscarriage. And through both the happy outcomes and the sad ones, your staff have been equally supportive and caring. You are all exceptional, and I hope you realise how much happiness you add to the world through your work.”
Page 26 - Annual report CRG
Scientific Research & Training Since its creation in 1983, the CRG has been driven by two strong engines: clinical practice, which is all about the patient, and (scientific) laboratory work, which supports and strengthens clinical practice.
ing of transgenerational effects of PCOS on health of the offspring; optimising success rates after fertility treatment in subfertile women with PCOS; reducing the risk of obstetric complications in pregnant women with PCOS.
Thanks to this powerful combination, the CRG - often together with the Centre for Medical Genetics (CMG) - has achieved several breakthroughs in the high-tech field of fertility medicine.
Reproductive endocrinology
Most of the research is conducted by scientific staff at the CRG laboratories. However, we also collaborate with other researchers. Genetic research mostly takes place in the laboratories of the CMG, for example. Together, the CMG and CRG make up the PGT clinic, where we try – by testing the embryos genetically before they are transferred to the prospective mother’s womb – to help couples with genetic problems to have a child free of the genetic defect. We also work with the Human Embryonic Stem Cell laboratory (hESC lab) and with the REGE (Reproductive Genetics), REIM (Reproduction and Implantation), FOBI (Follicle Biology) and BITE (Biology of the Testis) research groups of the Vrije Universiteit Brussel (VUB).
Research at the clinical level Polycystic Ovary Syndrome (PCOS) PCOS is one of the most common endocrine conditions in women of reproductive age. We have an active focus on translational and clinical research aimed at the understand-
Regarding ovarian stimulation, a lot of clinical questions remain unanswered. We are searching for the optimal protocol to treat poor responder patients in two clinical studies. Besides, progesterone at the end of the follicular phase is one of our hobbyhorses. Individualisation of the preparation of a frozen embryo transfer cycle is an important topic in our research. Another clinical study deals with the influence of the thyroid function on pregnancy outcome.
Endometrial receptivity and implantation To reach a successful implantation three elements are essential: a competent embryo, a receptive endometrium and an adequate synchronization between both. In several clinical research protocols we aim to further unravel the role of the endometrium in this rate-limiting step. Our goal is to better understand how it prepares for implantation/pregnancy and which factors influence the process. We hope to provide insights in pathologies like recurrent miscarriage and repeated implantation failure and work towards clinically applicable tests to evaluate endometrial receptivity.
Children follow-up Unique research into the pregnancies and children resulting from assisted conception.
Annual report CRG - Page 27
Research in the ART lab Laboratory techniques The aim is to improve existing techniques in the fertility clinic and to develop and validate new procedures in the following sub-domains: • laboratory techniques to fertilise an egg outside the body (IVF and ICSI); • conditions under which embryos grow outside the body; • the best way to freeze and store embryos; • the technique to remove a few cells from the embryo for genetic diagnosis (embryo biopsy); • the refinement and fine-tuning of existing techniques to check DNA mutations, hereditary disorders and chromosomal abnormalities in embryos.
Embryonic development and implantation of the embryo in the uterus Embryonic development starts when the egg is fertilised by a sperm cell. A fertilised egg develops into a multicellular embryo, a morula and a blastocyst. Research into embryonic development and implantation in-vitro is aimed at understanding why embryos grow poorly or do not implant. Our aim is a better understanding of the function of the genes and proteins that play a crucial role in early embryonic development. We hope this will lead to better diagnosis and treatment of couples with fertility problems.
Genetic state of the embryo This domain studies techniques to examine the DNA of embryos before they are returned to the uterus. The best-
known application is pre-implantation genetic testing (PGT), in which we remove a few cells or a little tissue from the embryo for analysis in the lab. There are two main reasons to genetically examine embryos: • to prevent embryos with a genetic disorder from being transferred in a fertility treatment; • to find out which genes play a role in embryonic development and implantation.
Embryonic stem cell research A human embryo of about five days old (the blastocyst) contains unique stem cells that, under certain conditions, can develop into any type of cell in the human body, such as nerve cells, muscle cells, blood cells, eggs and sperm. This research wants to investigate whether these stem cells can be used in the future to replace damaged cells in diseases such as Parkinson’s, heart failure and diabetes.
Genome modification The aim of this research is to determine whether it is possible to modify the DNA of a human embryo safely and efficiently. This can be useful for two reasons: • to avoid serious diseases by correcting the gene responsible for the disease; • to conduct scientific research on genes that play a crucial role in early embryonic development. We do this by eliminating them and studying their effects on embryonic development.
Page 28 - Annual report CRG
Research at the faculty The following research groups are associated with the CRG:
BITE: Biology of the Testis
REGE: Reproduction and Genetics
• Research focusses on the long-term effects of a testicular tissue biopsy procedure performed at young age • Developing and implementing methods to transplant spermatogenesis with a special focus on spermatogonial stem cells (SSCs) or testicular tissue • Generating sperm cells in-vitro • Studying Klinefelter Syndrome related infertility
• In a clinical framework, the CRG has joined forces with the CMG for a follow-up study into the health of children born using various assisted reproduction methods. Research is also carried out into the possible role of genetics in fertility issues, or simply put, into the possible genetic causes for male or female infertility • Fundamental research into embryonic stem cells and the possibility to use embryonic stem cells in regenerative medicine • Research into the origin of aneuploidy in human embryos • Research into the role of mitochondrial DNA variants in infertility and ART outcomes
FOBI: Follicle Biology • Research of oocyte in-vitro maturation (IVM), i.e. the culture or ripening of eggs in the laboratory • Research into the design of optimized culture systems for ovarian follicles and immature oocytes • Epigenetic safety testing of oocyte culture • Research into molecular makers that determine oocyte quality
REIM: Reproduction and Implantation • Research into the mechanisms that positively or negatively affect the development and the implantation of the embryo in the uterus, and • into the impact of the immune system on implantation.
Annual report CRG - Page 29
Selection of studies published in 2020 The proliferative phase endometrium in IVF/ICSI: an in-cycle molecular analysis predictive of the outcome following fresh embryo transfer. Mackens S, Santos-Ribeiro S, Racca A, Daneels D, Koch A, Essahib W, Verpoest W, Bourgain C, Van Riet I, Tournaye H, Brosens JJ, Lee YH, Blockeel C, Van de Velde H. Hum Reprod. 2020 Jan 1;35(1):130-144. Do we need to measure progesterone in oocyte donation cycles? A retrospective analysis evaluating cumulative live birth rates and embryo quality. Racca A, De Munck N, Santos-Ribeiro S, Drakopoulos P, Errazuriz J, Galvao A, Popovic B, Mackens S, De Vos M, Verheyen G, Tournaye H, Blockeel C Hum Reprod. 2020 Jan 1;35(1):167-174. A follow-up survey on the reproductive intentions and experiences of women undergoing planned oocyte cryopreservation. Wafi A, Nekkebroeck J, Blockeel C, De Munck N, Tournaye H, De Vos M. Reprod Biomed Online. 2020 Feb;40(2):207-214.
Characterization of the stem cell niche components within the seminiferous tubules in testicular biopsies of Klinefelter patients. Van Saen D, Vloeberghs V, Gies I, De Schepper J, Tournaye H, Goossens E. Fertil Steril. 2020 Jun;113(6):1183-1195.e3. Frozen-warmed blastocyst transfer after 6 or 7 days of progesterone administration: impact on live birth rate in hormone replacement therapy cycles. Roelens C, Santos-Ribeiro S, Becu L, Mackens S, Van Landuyt L, Racca A, De Vos M, van de Vijver A, Tournaye H, Blockeel C. Fertil Steril. 2020 Jul;114(1):125-132. Impact of endometrial polyps detected during the follicular phase of intrauterine insemination treatments. Schutyser V, Santos-Ribeiro S, Camus M, Boudry L, De Vos M, Tournaye H, Blockeel C. Reprod Biomed Online. 2020 Jul;41(1):62-68.
Modified natural cycle IVF is a reasonable alternative in women of advanced maternal age. Drakopoulos P, Romito A, Tournaye H, Blockeel C. Reprod Biomed Online. 2020 Apr;40(4):603.
Testicular immune cells and vasculature in Klinefelter syndrome from childhood up to adulthood. Willems M, Vloeberghs V, Gies I, De Schepper J, Tournaye H, Goossens E, Van Saen D. Hum Reprod. 2020 Aug 1;35(8):1753-1764.
To trigger or not to trigger ovulation in a natural cycle for frozen embryo transfer: a randomized controlled trial. Mackens S, Stubbe A, Santos-Ribeiro S, Van Landuyt L, Racca A, Roelens C, Camus M, De Vos M, van de Vijver A, Tournaye H, Blockeel C. Hum Reprod. 2020 May 1;35(5):1073-1081.
Is ovarian response associated with adverse perinatal outcomes in gnrh antagonist IVF/ICSI cycles? Bardhi E, Blockeel C, Cools W, Santos-Ribeiro S, Racca A, Mackens S, De Vos M, Polyzos NP, Popovic-Todorovic B, De Brucker M, Muzii L, Panici PB, Tournaye H, Drakopoulos P. Reprod Biomed Online. 2020 Aug;41(2):263-270.
Follicular-phase endometrial scratching: a truncated randomized controlled trial. Mackens S, Racca A, Van de Velde H, Drakopoulos P, Tournaye H, Stoop D, Blockeel C, Santos-Ribeiro S. Hum Reprod. 2020 May 6.
Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes. Segers I, Bardhi E, Mateizel I, Van Moer E, Schots R, Verheyen G, Tournaye H, De Vos M. Hum Reprod. 2020 Sep 1;35(9):2026-2036.
Preimplantation genetic testing with HLA matching: from counseling to birth and beyond. De Rycke M, De Vos A, Belva F, Berckmoes V, Bonduelle M, Buysse A, Keymolen K, Liebaers I, Nekkebroeck J, Verdyck P, Verpoest W. J Hum Genet. 2020 May;65(5):445-454.
Outcome of in-vitro oocyte maturation in patients with PCOS: does phenotype have an impact? Mackens S, Pareyn S, Drakopoulos P, Deckers T, Mostinckx L, Blockeel C, Segers I, Verheyen G, Santos-Ribeiro S, Tournaye H, De Vos M. Hum Reprod. 2020 Oct 1;35(10):2272-2279.
Page 30 - Annual report CRG
Multiple vitrification-warming and biopsy procedures on human embryos: clinical outcome and neonatal follow-up of children. De Vos A, Van Landuyt L, De Rycke M, Verdyck P, Verheyen G, Buysse A, Belva F, Keymolen K, Tournaye H, Verpoest W. Hum Reprod. 2020 Nov 1;35(11):2488-2496.
Early pregnancy loss in patients with polycystic ovary syndrome after IVM versus standard ovarian stimulation for IVF/ICSI. Mackens S, Mostinckx L, Drakopoulos P, Segers I, Santos-Ribeiro S, Popovic-Todorovic B, Tournaye H, Blockeel C, De Vos M. Hum Reprod. 2020 Dec 1;35(12):2763-2773.
Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy. D’Hondt C, Vanhoeij M, Van Moer E, Segers I, Fontaine C, Tournaye H, De Vos M. Breast Cancer Res Treat. 2020 Nov;184(2):433-444.
The freeze-all strategy versus agonist triggering with low-dose hcg for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial. Santos-Ribeiro S, Mackens S, Popovic-Todorovic B, Racca A, Polyzos NP, Van Landuyt L, Drakopoulos P, de Vos M, Tournaye H, Blockeel C. Hum Reprod. 2020 Dec 1;35(12):2808-2818.
SARS-COV-2 host receptors ACE2 and CD147 (BSG) are present on human oocytes and blastocysts. Essahib W, Verheyen G, Tournaye H, Van de Velde H. J Assist Reprod Genet. 2020 Nov;37(11):2657-2660. Combining fertility preservation procedures to spread the eggs across different baskets: a feasibility study. Delattre S, Segers I, Van Moer E, Drakopoulos P, Mateizel I, Enghels L, Tournaye H, De Vos M. Hum Reprod. 2020 Nov 1;35(11):2524-2536.
Expanding the time interval between ovulation triggering and oocyte injection: does it affect the embryological and clinical outcome? Vandenberghe LTM, Santos-Ribeiro S, De Munck N, Desmet B, Meul W, De Vos A, Van de Velde H, Racca A, Tournaye H, Verheyen G. Hum Reprod. 2020 Dec 24.
Annual report CRG - Page 31
PhD defenses at the faculty Dr. Annalisa Racca
Prof. dr. Shari Mackens
Elevated progesterone revisited: the fire is not yet extinguished
Hypes and hopes for endometrial receptivity in ART
Promotors: Prof. dr. C. Blockeel, Prof. dr. H. Tournaye The main aim of the thesis is twofold. First, to retrospectively investigate the association between progesterone level and embryo quality, embryo utilization rate and cumulative live birth rates, and to look into the outcomes from oocyte donorrecipient cycles in case of progesterone elevation. Second, to optimize freeze-all treatments, by comparing conventional live birth rates, and reduced multiple pregnancy rates, compared to a double embryo transfer. The results demonstrate that elevated progesterone is associated with reduced embryo quality and embryo utilization rate. In the first study, cumulative live birth rate also seemed affected; however, the later study focusing on freeze-all cycles could not confirm that finding. Oocyte donor-acceptor cycles did not show any adverse effect of elevated progesterone levels on embryo quality nor on any pregnancy outcome. When looking at the optimal protocol for frozen embryo transfer, the short protocol (one week) has comparable outcomes as the long protocol (two weeks). Also, there is no significant difference in live birth rate comparing single embryo transfer versus double embryo transfer. However, the rate of multiple pregnancies is significantly lower.
Promotors: Prof. dr. C. Blockeel, Prof. dr. H. Van de Velde, Prof. dr. H. Tournaye Human embryo implantation, the current rate-limiting step in ART, depends on three essential elements: a competent embryo, a receptive endometrium and an adequate synchronization between both. To this extent, the overarching research question of this thesis was whether endometrial receptivity can be optimized or predicted. Follicular-phase endometrial scratching during ovarian stimulation followed by a fresh embryo transfer did not increase the clinical pregnancy rate in a truncated randomised study and may be harmful as a higher clinical miscarriage rate was observed. A biomolecular study nested within this trial did not reveal significant differential gene expression in relation to the clinical outcome using transcriptome analysis of the whole-tissue endometrium, while the secretome profile of isolated, cultured and in-vitro decidualized endometrial stromal cells varied significantly between patients who had a live birth compared to those with an implantation failure. Genital tract microbiota research pointed out that ovarian stimulation significantly influenced the cervical microbiota composition and diversity. Furthermore, a DNA extraction protocol designed for low-biomass samples allowed to increase intra-uterine microbiota profiles quality. A randomised study in high-responders demonstrated that the freeze-all strategy did not harm the pregnancy rates in comparison with a fresh embryo transfer with an intensified luteal phase support, while it decreased the patient’s risk to develop moderate-to-severe ovarian hyperstimulation syndrome. Regarding frozen embryo transfer, retrospective data showed the late-proliferative phase serum estradiol level not to be useful to guide clinical decision-making in artificial cycles, while a randomized study in natural cycles demonstrated the spontaneous and triggered ovulation approach to perform comparably.
Page 32 - Annual report CRG
Investigator-initiated studies in the clinic
Influence of the microbiome on pregnancy outcome after IVF/ICSI (Microbiome-study). Blockeel C., Mackens S., Tournaye H. Effect of recombinant FSH dosing following corifollitropin alfa in patients undergoing IVF/ICSI in a GnRH antagonist protocol: a randomized controlled dose-finding study (CORIPRO study). Racca A., Blockeel C. Double trigger and ovum retrieval vs. conventional antagonist ovarian stimulation protocol in poor prognosis women undergoing IVF/ICSI: a randomized pilot study (DUOPICK study). Boudry L., Blockeel C. Natural cycle versus hormone replacement therapy cycle for a frozen-thawed embryo transfer in PGT patient (HRT_NC-FET study). Roelens C., Blockeel C. Clinical pregnancy rate for Frozen embryo transfer with HRT: a pilot study comparing 1 versus 2 weeks of treatment (Short-trial). Racca A., Blockeel C. Clinical efficacy of virtual reality for acute pain and anxiety management during outpatient hysteroscopy and endometrial biopsy in subfertility patients (HYSVIR trial). Schutyser V., Tournaye H. Initiation of ovarian stimulation with recombinanthuman FSH (Bemfola®) in the late follicular phase, a randomised controlled pilot study (D2D12Bemfola study). De Rijdt S., Blockeel C. Oral dydrogesterone (OD) versus micronized vaginal progesterone (MVP) for luteal phase support (LPS) in IVF/ICSI: pharmacokinetics and the impact on the endometrium, the microbiota of the genital tract and the peripheral immunology (DYDRA study). Mackens S., Blockeel C., Van de Velde H., Tournaye H.
Study on mitochondrial profiles of oocytes and granulosa cells in natural and stimulated cycles in oocyte donors (MITO-ART study). Spits C., Tournaye H., Blockeel C. Histological and Transcriptional Changes caused by Endometrial Flushing with Lipiodol: A Cross Over Study (Lipiodol study). Racca A., Blockeel C. Levothyroxine for euthyroid women with recurrent miscarriage and positive TPO antibodies (T4-LIFE study). Mackens S., Tournaye H. The influence of different thyroid autoantiboldies on thyroid function and preganancy outcome after assisted reproductive technologie (TGAB-study). Uvin V., Verpoest W., De Brucker M. A prospective observational study on the relationship between meiosis gene mutations and dysfunction of meiosis in oocytes (Meiosis dysfunction study). Verpoest W., Tournaye H., De Vos M., Van de Velde H. The Effect of Ulipristalacetate (UPA) on serum Antimüllerian hormone levels. Cosyns S., Tournaye H. Efficacy of Ulipristalacetate in comparison to surgery before IVF/ICSI-treatment in women with intramural fibroids: Effect on reproductive outcome. Cosyns S., Tournaye, H. The relationship between knowledge about the diagnosis of PCOS and quality of life, depression and anxiety A descriptive, cross-sectional study (PCOS_Knowledge paper). Mostinckx L., De Vos M. Translational research trial investigating the development potential of embryos obtained after in-vitro oocyte maturation (IVM) of oocytes from follicles < 10mm following a pre-maturation culture (Capacitation - CAPA-IVM) modulating the maintenance of meiotic arrest and the resumption of meiosis (IVM-CAPA study). De Vos M., Tournaye H., Segers I., Anckaert E.
Annual report CRG - Page 33
Conventional ovarian stimulation vs. in-vitro oocyte maturation (IVM) followed by in-vitro fertilisation (IVF): differences in patients’ emotional adjustment and quality of life (EMAQOL-study). De Vos M. A comparison between corifollitropin alfa and recombinant FSH for follicular recruitment in women with polycystic ovaries who undergo IVM treatment (IVM-ELONVA study). Segers I., De Vos M., Tournaye H. Novel molecular characterization of oocytes and cumulus cells from women with polycystic ovarian syndrome (PCOS) phenotype A (IVM-MOLPA). Anckaert E., De Vos M. A randomized controlled trial to evaluate whether pretreatment with myo-inositol can lower testosterone levels and improve clinical outcomes in hyper androgenic PCOS patients undergoing ART (Gynositol study). De Rijdt S., Blockeel C., De Vos M. Endometrial preparation using letrozole compared to artificial cycle for frozen embryo transfer in PCOS patients (LEFT). Boudry L., De Vos M., Blockeel C.
Detection of SARS-CoV-2 in semen of COVID-19 positive males (COVID_SPERM study). Uvin V., De Brucker M., Verheyen G. Detection of SARS-CoV-2 in follicular fluid and cumulus-oocyte-complexes from COVID-19 patients during controlled ovarian stimulation for ICSI treatment (COVID_OFF study). Boudry L., Van de Velde, H. Follow-up of fertility in young adults who did or did not store testicular tissue before gonadotoxic treatment for fertility preservation. Braye A., Goossens E., Tournaye H., Vloeberghs V., Gies I., Van der Werff Ten Bosch J. COmbining Interventions of fertility preservation to Mitigate fertility loss after BReAst cancer (COIMBRA). Delattre S., De Vos M. Autologous testicular tissue transplantation for fertility restoration. Vloeberghs V., Tournaye H.
Page 34 - Annual report CRG
Sponsored studies in the clinic A randomized, double-blind, placebo-controlled, parallell-group, dose-range trial to investigate the efficacy and safety of FE 999302 as add-on treatment to follitropin delta (REKOVELLE) in women undergoing controlled ovarian stimulation in a long GnRH agonist protocol: RAINBOW. Blockeel C., Tournaye H. IMPLANT 4: A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to increase ongoing pregnancy rate following fresh single blastocyst transfer resulting from IVF: IMPLANT 4. Blockeel C., Tournaye H. Transdermal testosterone gel for poor ovarian responders. A multicentre double-blind placebo controlled randomized trial (TTransport study). Blockeel C., Tournaye H.
Hyalobarrier®GEL ENDO versus no Hyalobarrier®GEL ENDO following operative hysteroscopy for improving reproductive outome in women with intrauterine pathology wishing to become pregnant (AGNOHSTIC trial). Schutyser V., Tournaye H. VIDAS® HCG study on women with ectopic pregnancy (VIDAS trial). Anckaert E., Blockeel C., Tournaye H. Prospective Multicentre non-Interventional Study to Assess the Patterns of Use of REKOVELLE in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice: PROFILE. Blockeel C., Tournaye H.
Annual report CRG - Page 35
Studies in the IVF-laboratory Blastocyst-stage versus cleavage-stage transfer: neonatal follow up of singletons born from three randomized controlled trials. De Vos A. Fertility treatments in PCO(S) patients: what are the success rates and risks after an in vitro maturation (IVM) treatment compared to a standard controlled ovarian stimulation (COS). De Vos M., Segers I. Cumulus cel mRNA analyse als eicel kwaliteitstest in het fertiliteitslaboratorium. Anckaert E. Trial investigating the developmental potential of embryos obtained after biphasic in vitro oocyte maturation (IVM) of oocytes including a pre maturation culture step (‘capacitation step’) compared with standard IVM. (IVM-CAPA Sibling study). De Vos M., Verheyen G., Segers I., Anckaert E. Effect of abstinence duration on embryo development: a prospective sibling study. Mateizel I. Embryo culture at a stable temperature of 36.6°C or 37.1°C: a randomized study. Wouters K. Blastocyst culture using G-TL single-step versus Origio sequential medium: a semi-randomized approach. Mateizel I. Does the freezing-warming procedure cause cellular damage on day 3 embryos? A retrospective observational study discussing obstetrical outcomes. Racca A., Di Guardo F., Blockeel C., Van Landuyt L., Verheyen G.
Reproductive Skills Centre Brussels The Reproductive Skills Centre Brussels (RSCB) is CRG’s ART training centre. The RSCB consists of a training room with two complete ICSI and vitrification set ups and a clinical training room with simulators for oocyte pick-up, embryo transfer, hysteroscopy and laparoscopy. The courses offered in the RSCB provide comprehensive training in the clinical and laboratory aspects and practices of assisted reproductive technologies and reproductive surgery. The courses are given by experienced clinicians and embryologists in both in-depth theoretical lectures and hands-on sessions under expert supervision.
All courses include: • • • • • •
Theoretical sessions & lectures Case studies Teaching & demo videos Hands-on laboratory & clinical training sessions Q&A – Interactive discussion Guided tour of the Centre for Reproductive Medicine
The RSCB is led by Prof. dr. Herman Tournaye, Clinical and Scientific Director at the Centre for Reproductive Medicine. Faculty include senior CRG staff. The Reproductive Skills Centre Brussels is located in the Centre for Reproductive Medicine at the university hospital UZ Brussel.
Get in touch: rscb.brusselsivf.be rscb@uzbrussel.be
Laboratory workshops Clinical workshops Intra-Cytoplasmic Sperm Injection
Vitrification
Embryo biopsy for PGT
Oocyte retrieval & embryo transfer: advanced course
Fertility in the OR: focus on diagnostic hysteroscopy
In-vitro maturation
Laboratory design and start-up
Reproductive Skills Centre Brussels
Quality management and control
Page 38 - Annual report CRG
• DONDERDAG 5 MAART
CRG IN THE PRESS
in ons Jaarlijks beginnen end land meer dan duiz of vrouwen van 40 jaart, in ouder een ivf-trajecnger de hoop alsnog zwa er te worden. Dat zijn als ruim dubbel zo veel tien jaar geleden. Gespecialiseerde artsen waarschuwen voor overdreven verwas Nicole Kidman wachtingen. toen ze voor het “Op die leef- eerst moeder werd de zijn tijd sen slaagkan erg beperkt”, zegt professor Herman Tournaye. “Veel kleiner dan de succesverhalen uit de boekskes doen vermoeden.”
41
’t als in de boekskes
AN MUNTERS (34) Vier jaar geleden kreeg An Munters (34) uit Gingelom de harde diagnose van borstkanker. De goedlachse Limburgse liet tussen een operatie en chemokuur eicellen invriezen. “Een lichtpuntje in die donkere periode.”
“Oncofreezing was lichtpuntje in donkere periode”
“We hebben geen we toverstokje waarmee en.” iedereen zwanger krijg
FOTO KAREL HEMERIJCKX
CHRISTOF SCHRAEPEN (42) De touwtjes in handen nemen. Dat was de eerste reactie van Christof Schraepen en zijn echtgenote Nathalie Bosmans toen de kankerdiagnose viel. “Binnen de week hadden we de oncofreezing achter de rug.”
“We waren de dokters te snel af” Het was een geluk bij een ongeluk voor Christof (42). Als drager van het BRCA2-gen, beter bekend als het borstkankergen, werd zijn bloed vaak gecontroleerd. Daardoor merkten artsen al snel dat er iets scheelde. Eind mei 2017 kreeg Christof het verdict: prostaatkanker. “We maakten ons niet meteen zorgen. De verhoogde bloedwaarde kon ook wijzen op een ontsteking. Pas na de punctie door de uroloog wisten we zeker dat het kanker was. Mijn prostaat moest verwijderd worden. Ik zou geen kinderen meer kunnen krijgen op een natuurlijke manier.” Omdat er bij het BRCA2-gen 50% kans is dat je het gen overdraagt op je kinderen, volgden Christof en Nathalie al een vruchtbaarheidsbehandeling in het UZ Brussel. Succesvol, want op het moment van de kankerdiagnose was Nathalie zwanger van een gezonde dochter. Het koppel
FOTO KAREL HEMERIJCKX
HBvLPLUS
kon daardoor snel in het UZ terecht. “We waren de oncologen voor. Toen zij ons inlichtten over oncofreezing hadden wij alles al achter de rug. Twee dagen na het gesprek met de uroloog hadden we de papieren voor het invriezen al getekend, op een dag na een feestdag. Eigenlijk was het Fertiliteitscentrum toen gesloten, maar we werden toch geholpen.” Het koppel is tevreden over de stappen die ze genomen hebben om voor zichzelf die zekerheid in te bouwen. “Op dat moment was ik er nochtans niet mee bezig hoe belangrijk dat is. Genezen kwam op de eerste plaats”, zegt Christof. “Mij stelde dat invriezen toen net wel gerust”, reageert Nathalie. “Als we op termijn nog een tweede kindje willen, is dat tenminste niet uitgesloten.” Christof: “Daarom heb ik jou, hé (lacht). Jij dacht daar wel over na.”
ZATERDAG 29 FEBRUARI EN ZONDAG 1 MAART 2020
hbvl.be
4
Steeds meer kankerpatiënten houden kinderwens levend in de vriezer
ONCOFREEZING Steeds meer kankerpatiënten kiezen er vóór het begin van hun behandeling voor om eicellen, zaadcellen of zelfs eierstok- of teelbalweefsel te laten invriezen. Dankzij deze techniek, die oncofreezing wordt genoemd, kunnen patiënten hun kinderwens levendig houden.
Door Kato Poelmans
SEBBE STEVENS (28)
I
Kinderwens al 17 jaar bevroren
n 2018 deden 524 jonge kankerpatiënten in België een beroep op oncofreezing. Het Centrum voor Reproductieve Geneeskunde (CRG) van UZ Brussel, dé pionier in ons land op het vlak van vruchtbaarheidsbehandelingen, ziet jaarlijks zo’n 80 kankerpatiënten voor een dergelijke behandeling. Een verdubbeling ten opzichte van het begin van hun metingen in 2012. Die stijging is niet verwonderlijk, volgens prof. dr. Michel De Vos en dr. Veerle Vloeberghs van het CRG. “Mond-totmondreclame en de groeiende media-aandacht spelen daarin een belangrijke rol. Ook cruciaal is dat de behandeling volledig wordt terugbetaald sinds april 2017. Zonder de terugbetaling zou het een duur proces zijn voor patiënten, met prijzen die oplopen tot 3.400 euro.”
Een kankerdiagnose op 11-jarige leeftijd is zwaar. Een experimenteel onderzoek om een eventuele kinderwens in de toekomst niet weg te nemen, maakt het nog veel moeilijker. Zeventien jaar later is de kanker bij Bilzenaar Sebbe Stevens (28) weg, maar die kinderwens is een vraagstuk gebleven.
Wat is oncofertiliteit? Dr. Veerle Vloeberghs: “Oncofertiliteit is het bewaren van de vruchtbaarheid vooraleer de kankerbehandeling wordt gestart. Die behandelingen, zoals chemo- of radiotherapie, kunnen erg schadelijk zijn. Je kan er blijvend onvruchtbaar van worden.” Prof. De Vos: “Het is eigenlijk pas de laatste tien jaar dat we hebben ontdekt dat veel van de technieken die we gebruiken om koppels met vruchtbaarheidsproblemen te helpen, ook kunnen worden gebruikt voor mensen met kanker. Vroeger was het invriezen van eicellen quasi onmogelijk.” Wat is er veranderd? Prof. De Vos: “Als je cellen met veel vocht invriest, ontstaan er ijskristallen. Bij het dooien snijden die ijskristallen als messen in de eicel, waardoor die kapot gaat. Invriezen van eicellen lukte dus niet, tot er zo’n tien jaar geleden een nieuwe techniek werd ontwikkeld, flitsvriezen.
Daarbij worden cellen zo snel afgekoeld dat die ijskristallen zich niet kunnen vormen, waardoor de eicel het vriesproces overleeft.” Dr. Vloeberghs: “Voor het invriezen van zaadcellen gebruiken we een andere techniek: slowfreezing. Dat was dus al langer mogelijk.” Prof. De Vos: “Het vriezen gebeurt dan in verschillende stappen. We beginnen op 37 graden en koelen af tot -196 graden. Dat is de temperatuur waarop voortplantingsmateriaal wordt bewaard.”
Dr. Veerle Vloeberghs en dr. Michel De Vos van het Centrum voor Reproductieve Geneeskunde in Brussel. FOTO GUY PUTTEMANS
HBvLPLUS
Welke verschillende behandelingen bestaan er? Prof. De Vos: “Vrouwen kunnen eicellen, eierstokweefsel of een embryo laten invriezen. Eierstokweefsel wegnemen kan zonder hormonale behandeling. Eicellen weghalen betekent wél een hormonale behandeling. Dat hebben sommige vrouwen liever niet. De keuze tussen die
“Zonder de terugbetaling zou het een duur proces zijn voor patiënten, met prijzen die oplopen tot 3.400 euro” dr. Michel De Vos
behandelingen is niet gebaseerd op efficiëntie, omdat we gewoonweg nog niet weten wat de slaagcijfers zijn.” Dr. Vloeberghs: “Bij een man die de puberteit voorbij is, is het meestal gemakkelijk. Dan vriezen we zaadcellen uit een zaadlozing in. Dat is niet ingrijpend. Bij jongens die nog niet in de puberteit zijn, is het veel moeilijker. De enige optie is een stukje teelbalweefsel met stamcellen wegnemen om in te vriezen.” Wat gebeurt er met dat weefsel na een succesvolle kankerbehandeling? Prof. De Vos: “We kunnen helaas nog geen onrijpe eicellen in een petrischaaltje laten rijpen. We moeten dus een ingreep doen en het eierstokweefsel terug in de buik inplanten. De eerste baby na zo’n terugplaatsing is in België geboren in 2004. Sindsdien zijn er zo ongeveer 200 baby’s
ZATERDAG 29 FEBRUARI EN ZONDAG 1 MAART 2020
hbvl.be
2
geboren.” Dr. Vloeberghs: “Voor mannen gaat het om een erg experimentele techniek. Op dit moment is er wereldwijd nog geen enkele terugplaatsing van teelbalweefsel geweest bij de mens. Wij kunnen dat weefsel niet transplanteren als we niet zeker zijn dat daar geen kankercellen in zitten. Bij apen is dat wel al gelukt.” Staat er een houdbaarheidsdatum op ingevroren voortplantingsmateriaal? Prof. De Vos: “In België is de wettelijke termijn voor het invriezen van weefsel op tien jaar vastgelegd, maar we kunnen dat verlengen om medische redenen. Puur medisch gezien is de houdbaarheidsdatum zelfs na tien jaar nog niet verstreken.”
HBvLPLUS
nen met ivf 8%
34,6% 36,
In 2018 werden 62.812 Vlaamse vrouwen moeder. Amper 0,2% was
14,9% 9,4% 1,2%
45 jaar of ouder.
voor Bron: Studiecentrum gie Perinatale Epidemiolo
2,9% 0,2%
> 44 jaar 35-39 jaar 40-44 jaar 25-29 jaar 30-34 jaar < 20 jaar 20 -24 jaar
dus. goede prognoses gemen ans geregeld Geen “Iets wat nocht de media”, “Maar dan heeft de over iemand uit nog aan bod komt in Ombe- hoord die op haar 43ste zegt professor Willem Oost-Lim- buurt is geraakt let van Ziekenhuis te zien in spontaan zwanger nog niet burg, momenteel “Toch is en denkt men het is n zichVier. gunne op en kters e te laat. Mens dr. Tour- Topdo voordeel van de daar onvoldoend bij de veertig”, zegt en. je er- men zich st. Er zijn zelfs zelf altijd het moet je dan het om 454 vrouw d in naye. “Maar nooit lees n twijfel. Als artsen temperen. voorrang, ging ap tot van bewu De carrière kreeg ontbrak, “De gemiddelde leeftijjaar”, bij hoe die zwangersch als huisartsen en gynaecologe de verwachting er 35 n dat we een vrouw ren koppels het kwam. In zo goed de geschikte partn lang op ons centrum is zo’n eicel- die denke g 44 jaar makke- Vaak probe keer met eigen liet “Vrouwen stand met aye. dat is Tourn en dr. de kinderwens alsnog één n een alle gevall exacte re- zegt afkom- van pakwe n ze het hebbe zich wachten... De vrouwen van boven de 40 blijve aan- donatie. Met eicellen stijgt lijk nog zwanger krijgen.” Dan n. eicelle hun en aan hebden waarom meer bij de minderheid. Maar van jonge donor gevoel dat ze er alles 40 vaak stap- stig zijn ze niet ans, tot één op drie. van boven de iniek aan- deel groeit wel. En ben gedaan, maar proberen.” over- de slaagk koppels zien dat Erg belastend veel vruchtbaarheidskl we niet. pen ze binnen met blijven en. Het Maar dien is n kans nodeloos ject kan erg belaskloppen, kenne duidelijk”, dreven verwachting een to- niet zitten, en boven n in Voorbij de 40 jaar is de n Een ivf-tra is aan eicelle dat dokters mentaal. En een kind te krijge leeft tekort ook “Maar de trend een idee alsnog zijn, er om ze tend Touree an van ivf erg de terugzegt professor Herm el. Hij verstokje hebben waarm zelfs met de hulp Ombelet bovendien stopt st krij- België.” Bruss sor naye van het UZ kat de bel alle problemen opgelo klein, legt profes we eicellen betaling vanaf 43 jaar. wanzelf Eén kans op twaalf bond dinsdag de Humo. uit. “Per keer dat vrouw van “Iedereen kiest NAYE lad ren wil beeen aan in het weekb zien meer HERMAN TOUR eid weghalen bij en 43 jaar, is de neer hij met kinde De vruchtbaarh Fertiliteitsartsen PROF UZ BRUSSEL zegt dr. Ombelet. de 40 n”, in tussen en ginne daalt en vrouw ij mag daar van een vrouw vrij kans dat er een kind gebor en meer ‘oudere’ tie “De maatschapp en. Toch is evolu Bij een f. 35ste zaal, twaal haar op vanaf hun wacht niemand in dwing campagne aan- wordt één tigd door de spectaculair. Het t af, vrouwen van 43 jaar of ouder die wordt beves er nood aan een s. Uit het een op vijftig.” die duidelijk maakt hoe fel de tal eicellen neem officiële cijfer rt, met ervan zelfs maar en de kwaliteit jd is Ook belangrijk: met de leef- kansen slinken voorbij de 40 meest recente rappo blijkt dat vermindert. Leefti die tijd stijgt de kans op een mis- jaar. Mensen moeten dat wecijfers uit 2017, nd vroude bij duize factor te n ze hun zo’n ingen ks grijks afwijk jaarlij de belan ten. Dan nog kunne eid, kraam en zo.” of ouder een Maar dat is niet op de vruchtbaarh r- foetus. “Ook dat beseft men eigen keuzes maken.” wen van 40 jaar nen in een gen. geld duiken er in de weegt doende.” grijker dus dan bijvoo ivf-traject begin tbaarheids- “Gere van zwan- belan roken of overgewicht. vaak onvol Belgische vruch ruim dub- boekskes foto’s op beeld voorver er van zijn celebrities kliniek. Dat 2007. Toen gere bel zo veel als in
Door Kato Poelmans
bij de dokter en moesten we ineens knopen doorhakken over een deel van de toekomst waar we nog niet mee bezig waren. Dat was moeilijk.” Toch kijkt An, ondanks de zware behandelingen, positief terug op die periode. “Ik durf zelfs zeggen dat oncofreezing gedurende 28 dagen een lichtpuntje was. Het was een investering in de toekomst. Door de antihormoontherapie die ik nu nog krijg, zal ik de 35 gepasseerd zijn voordat ik aan kinderen kan beginnen. Soms is dat wel pijnlijk. Vooral omdat de omgeving rondom me niet stilstaat. Ik zie vriendinnen gezinnetjes stichten, terwijl ik dat zelf nog niet kan en mag. Maar ik maak me niet druk. Wetende dat mijn vriend en ik mogelijkheden hebben met die ingevroren eitjes, hebben wij de knop kunnen omdraaien. Wij leven nu van dag tot dag, we pakken alles zoals het komt.”
was Céline Dion toen ze een tweeling kreeg
en boven de 40 begin
Dubbel zo veel vrouw
OisPnGietEzoLsiEmTpe:l
11
42
was Gwen Stefani toen ze beviel van haar derde kind
JONAS MAYEUR
LIMBURGSE KANKERPATIËNTEN HOUDEN KINDERWENS LEVEND IN DE VRIEZER
“In augustus 2015 kreeg ik de diagnose ‘hormoongevoelige borstkanker’. Een agressieve kanker, dus een dubbele borstamputatie en chemo waren nodig. Dat was het cadeau voor mijn dertigste verjaardag. Brute pech.” “Als je dat nieuws krijgt, raak je in paniek. Ik schoot in overlevingsmodus. Dat ik onvruchtbaar kon worden, daar was ik niet mee bezig. Gelukkig werd ik goed begeleid in het Borstcentrum van het Jessa Ziekenhuis. Zij verwezen me door naar het Fertiliteitscentrum in Jette.” Tussen de operatie en de chemo had An zes weken tijd om eicellen te laten invriezen. “Geen evidente beslissing. Toen ik ziek werd, hadden mijn vriend en ik amper over kinderen gesproken. We waren allebei 30 en hadden een kinderwens, maar er was nog geen ‘wanneer’ opgeplakt. Dan zaten we daar
44
2020
30 oktober 2003. De datum staat voor altijd in het geheugen van Sebbe gegrift. Het begin van de herfstvakantie, maar voor de toen elfjarige Sebbe vooral het begin van een lang ziekteproces. “Ik had mijn amandelen laten wegnemen. Twee weken later was ik nog steeds niet hersteld. Wittekes, lijkbleek. Ik liet bloed nemen en op 30 oktober kreeg ik telefoon: Ga maar naar het ziekenhuis. Er scheelt iets. De dokter wist niet hoe of wat, maar mijn bloedwaarden waren niet goed. ’s Morgens zat ik op spoed, ’s avonds kreeg ik de diagnose: leukemie.” Het begin van een lange strijd voor de jonge Sebbe met behandelingen die heel schadelijk kunnen zijn voor de vruchtbaarheid. De artsen begonnen met een zware chemokuur. Die sloeg niet aan: het gevolg van een schimmel in zijn lichaam die door de chemo was beginnen groeien. Na een behandeling met een gloednieuw medicijn tegen de schimmel tot dan nog nooit getest op mensen -, een nieuwe chemokuur en een beenmergtransplantatie had Sebbe de kanker eindelijk verslagen. Vóór al die behandelingen liet Sebbe teelbalweefsel wegnemen en invriezen. Een experimentele ingreep om een eventuele kinderwens jaren later nog een kans te geven. “Op een dag stond dokter Tournaye (diensthoofd van het Centrum voor Reproductieve Geneeskunde van UZ Brussel, nvdr.) aan het voeteneinde van mijn ziekenhuisbed. . Ik zei direct ja. Natuurlijk. Wat moest ik zeggen? Uiteindelijk was dat op dat moment het beste wat ik kon doen voor later. Mijn ouders zullen me daar wel in gestuurd hebben, als elfjarige ben je daar tenslotte helemaal niet mee bezig. Maar ik kreeg wel veel inspraak in de beslissing.” Zeventien jaar later blijkt Sebbe, die nu in Denderleeuw woont, inderdaad onvruchtbaar door de zware kankerbehandelingen. Zijn kinderwens blijft voorlopig ongewild on hold staan. “Het teelbalweefsel dat ze hebben ingevroren, is uitvoerig getest en er zit goed weefsel bij. Zwemmerkes dus, hoewel ik maar elf jaar oud was. Tot daar het goede nieuws. Cruciaal is nu dat dat weefsel voor 100% gezond wordt verklaard, maar daarover kunnen de artsen voorlopig nog geen uitsluitsel bieden. Voor hetzelfde geld plaatsen ze het terug en krijg ik opnieuw kanker. Ze willen ook geen enkele kunstmatige bevruchting doen met ongezonde zaadcellen. Mogelijke kwaadaardige cellen moeten er eerst uit, maar dat kunnen de artsen nog niet. Nu
FOTO GUY PUTTEMANS
“Voor hetzelfde geld plaatsen ze het weefsel terug en krijg ik opnieuw kanker” Sebbe Stevens
hebben ze voor 98% zekerheid dat het gezond weefsel is. Wat is die 2% dan nog?” “Ik kan nog geen kinderen krijgen en daar heb ik het moeilijk mee. In relaties loopt het daardoor vaak mis. In het begin praat je er niet over, maar er komt altijd een moment dat het wel ter sprake komt. Dat is lastig, maar ik kan er zelf natuurlijk niets aan doen. Ik kan mezelf niets kwalijk nemen. In theorie is de onvruchtbaarheid trouwens omkeerbaar, maar voorlopig is dat bij mij niet het geval. Door een nieuwe hormoonbehandeling te starten, zijn we nu wel aan het testen of de natuurlijke productie van zaadcellen toch op gang zou kunnen komen. Er is dus nog een kleine kans, maar ik ga er geen hoop op zetten. Het zal nu aan dokter Tournaye zijn om zich te bewijzen. Maar als ik niet geholpen kan worden met het ingevroren weefsel, dan stopt het voor mij en zal ik nooit zelf kinderen kunnen krijgen.”
ZATERDAG 29 FEBRUARI EN ZONDAG 1 MAART 2020
hbvl.be
3
Annual report CRG - Page 39
GAZET VAN ANTWERPEN
BINNENLAND
RACISME EN SEKSISME Politica’s steunen oproep Antwerpse Sihame El Kaouaki bi (Open Vld) om niet langer te zwijgen
G e n o e g van de bagger Sihame El Kaouakibi Open Vld
“Als op de duur 80% van alle reacties bagger zijn en een heel trollenleger achter je aan zit, dan moet je een lijn trekken.”
Tot hier en niet verder. De huid kweken en immuun seksuele en racistische verworden voor drek die ze over wijten moeten stoppen. Het zich heen krijgt. “Ik wil wel is de boodschap van Anthard werken in de politiek, werps Open Vld-politica Simaar niet hard worden”, zegt hame El Kaouakibi, die giste- ze. ren op sociale media aan de alarmbel trok en daarvoor Potentiële schietschijf heel veel bijval kreeg van anLiesbet Stevens van het Indere politica’s. “Sinds ik de stituut voor de Gelijkheid stap naar de politiek zette, van Vrouwen en kan ik geen Facebookbericht, steunt de oproep Mannen van El Kavideo of idee meer posten of ouakibi volledig. Zij stelt vast de riool gaat open. We modat seksisme in de lift gen daar niet meer over zwij- daar niet verbaasdzit en is over. gen.” “Vooral vrouwen zijn online het slachtoffer van seksuele Moslimhoer. Zandbakvlo. intimidatie. En politica’s zijn Poedelkop. Met uw soort daar net zoals feministes kunnen we niet ranzig ge- mensenrechtenactivisten of noeg zijn. Het zijn maar en- vaak het mikpunt, zeker als kele verwijten die El Kaoua- ze ook een kleur hebben. Als kibi de voorbije weken en ik cru mag zijn: elke vrouw maanden naar het hoofd ge- met een mening is een potenslingerd kreeg. Ze was al ja- tiële schietschijf.” ren bekend, maar sinds ze Het is volgens Stevens een politiek actief is, is de stop er poging om vrouwen mondop sociale media helemaal dood te maken. Velen haken af. “In het begin probeerde ik door de bagger ook effectief het te negeren, maar als op af. “Het is cynisch dat sommide duur 80% van alle reacties gen de vrije meningsuiting zo zijn en een heel trollenle- gebruiken om anderen het ger achter je aan zit, dan zwijgen op te leggen.” moet je een lijn trekken.” Niet alleen in ons land, Vandaar de oproep op socia- maar overal doet het prole media aan iedereen die bleem zich voor. Cijfers van bagger over zich heen krijgt de Verenigde Naties geven om daar niet meer over te aan dat vrouwen 27 keer zwijgen. “Ja, wij zijn politici. meer kans lopen op verbaal En ja, er is veel wantrouwen geweld. Maar liefst 73% zegt en boosheid en wij mogen ooit al te maken hebben geveel kritiek krijgen, maar doe had met online misbruik. In dat met respect.” twee op de tien gevallen De liberale politica wil naar het om ernstig geweld. gaat eigen zeggen geen olifantenEls Keytsman van het Inter- FOTO'S RR
Dubbel zoveel vrouwen boven de 40 beginnen met ivf
Jaarlijks beginnen in ons land meer dan duizend vrouwen van 40 jaar of ouder een ivf-traject, in de hoop alsnog zwanger te worden. Dat zijn er ruim dubbel zo veel als tien jaar geleden. Gespecialiseerde artsen waarschuwen voor overdreven verwachtingen. “Op die leeftijd zijn de slaagkansen erg beperkt”, zegt professor Herman Tournaye. “Veel kleiner dan succesverhalen uit de boekskes doen vermoeden.”
Fertiliteitsar tsen zien steeds meer ‘oudere’ vrouwen in hun wachtzaal, een evolutie die de officiële cijfers bevestigen. Uit cijfers uit 2017 blijkt dat jaarlijks zo’n duizend vrouwen van 40 jaar of ouder een ivf-traject beginnen in een Belgische vruchtbaarheidskliniek. Dat zijn er ruim dubbel zo veel als in 2007. Toen ging het om 454 vrouwen. “De gemiddelde leeftijd in ons centrum is zo’n 35 jaar”, zegt Tournaye. “Vrouwen van boven De exacte reden waarom meer de 40 blijven een minderheid, vrouwen van boven de 40 bij de maar hun aandeel groeit. En vaak vruchtbaarheidskliniek aanklop- stappen ze binnen met overdrepen, kennen we niet. “Maar de ven verwachting en.” trend is duidelijk”, zegt professor “Geregeld duiken er in de boekHerman Tournaye (foto) van het skes foto’s op van zwangere celeUZ Brussel. Hij bond dinsdag de brities van ver voorbij de 40”, zegt kat de bal aan in het weekblad Tournaye. “Maar nooit lees je erHumo. bij hoe die zwangerschap tot
DONDERDAG 5 MAART 2020
11
federaal Gelijkekansencentrum Unia zegt dat het daarom belangrijk is dat ook over online geweld wordt gesproken. “Het gaat om geweld en niet zomaar het verkondigen van een mening. En we moeten het signaal geven dat we dit niet zomaar pikken”. Keytsman was zelf ooit het slachtoffer van anonieme online bedreigingen. Ze diende een klacht in en kon er uiteindelijk voor zorgen dat haar belager werd veroordeeld.
Eelt op de ziel Zowel Keytsman als Liesbeth Maris, voorzitter van Vrouw & Maatschappij (CD&V), wijst erop dat vrouwelijke politici en zeker politica’s met allochtone roots hard worden aangepakt. Groen-voorzitster Meyrem Almaci kloeg het probleem al verschillende keren aan. “Zelfs wanneer ik een recept van pannenkoeken tweet, krijg ik drek over me heen. Vetgemeste koe, leider van de makakkenpartij, om het even wat. Ik ben het favoriete mikpunt van velen. Omdat ik voorzitter, vrouw, allochtoon en mondig ben. Ik heb na twaalf jaar veel eelt op de ziel, maar eigenlijk is dat fout. We moeten dit blijven aanklagen. Als zelfs Gwendolyn Rutten zegt dat ze Twitter van haar gsm heeft gezwierd...” Volgens El Kaouakibi en Almaci wordt het ook alleen maar erger. “Vroeger was het alleen maar online, maar nu heeft het ook impact op het werkelijke leven. Trollen die anoniem verhalen fabriceren en dingen insinueren in de hoop dat er toch maar iets blijft hangen. En om zo stemmen bij je weg te halen. 280 tekens lijken niet veel, maar ze kunnen een verwoesting aanrichten”, zegt Almaci. FARID EL MABROUK
Geen goede prognoses dus. “Maar dan heeft men gehoord over iemand uit de buurt die op haar 43ste nog spontaan zwanger stand kwam. In zo goed als alle is geraakt en denkt men het is nog gevallen is dat met eiceldonatie. niet te laat. Mensen gunnen zichMet eicellen afkomstig van jonge zelf het voordeel van de twijfel. donoren stijgt de slaagkans tot Als arts moet je dan de verwacheen op drie. Maar veel koppels tingen temperen. Vaak proberen zien dat niet zitten.” koppels het alsnog één keer met De vruchtbaarheid van een eigen eicellen. Dan hebben ze het vrouw daalt vanaf haar 35ste vrij gevoel dat ze er alles aan hebben spectaculair. Het aantal eicellen gedaan, maar zijn ze niet nodeneemt af, en de kwaliteit ervan loos blijven proberen.” Een ivfvermindert. Leeftijd is de belangtraject kan erg belastend zijn, ook rijkste factor die weegt op de mentaal. Bovendien stopt de tevruchtbaarheid, belangrijker dus rugbetaling vanaf 43 jaar. dan bijvoorbeeld roken of overge- FOTO BELGA “Iedereen kiest zelf wanneer hij wicht. een vrouw van tussen de 40 en met kinderen wil beginnen”, zegt 43, is de kans dat er een kind ge- Ombelet. “De maatschappij mag Kans van één op twaalf boren wordt één op twaalf. Bij daar niemand in dwingen. Toch Voorbij de 40 jaar is de kans om vrouwen van 43 jaar of ouder er nood aan een campagne is alsnog een kind te krijgen zelfs zelfs maar die een op vijftig.” Ook be- duidelijk maakt hoe fel de kansen met de hulp van ivf erg klein, legt langrijk: met de leeftijd stijgt de slinken voorbij de 40 jaar. Mensen professor Willem Ombelet Zie- kans op een miskraam en afwij- moeten dat weten. Dan nog kunkenhuis Oost-Limburg uit. “Per kingen bij de foetus. “Ook dat be- nen ze hun eigen keuzes maken.” keer dat we eicellen weghalen bij seft men vaak onvoldoende.” (jom)
CONTACT US www.brusselsIVF.be www.uzbrussel.be CONTACT CENTRE +32 2 477 66 99
© Centrum voor Reproductieve Geneeskunde This material is protected by copyright. No part of this report may be reproduced without prior permission in writing from the responsible publisher. Inappropriate or unlawful use is an infringement of the copyright and is a criminal offence.
DEDICATED WEBSITES Oncofertility: www.brusselsoncofertility.be PGT: www.brusselsgenetics.be Sperm donation: www.spermadonor.be
Photography: © Bart Moens © Ahmed Ben Afennas © UZ Brussel Responsible publisher: Ulrike Dragon Centrum voor Reproductieve Geneeskunde Universitair Ziekenhuis Brussel Laarbeeklaan 101 1090 Brussel Belgium Publication date: May 2021
Egg donation: www.idonatehappiness.be Reproductive Skills Centre Brussels (RSCB): www.rscb.brusselsivf.be Next Level IVF Clinic: http://next-level-ivfclinic.brussels Follow CRG on Twitter: @BrusselsIVF Explore the CRG in a virtual tour: